The paper Association between eating behavior patterns and the therapeutic efficacy of GLP-1 receptor agonists in individuals with type 2 diabetes: a multicenter prospective observational study was authored by Yuya Koide, Takehiro Kato, Makoto Hayashi, Hisashi Daido, Takako Maruyama, Takuma Ishihara, Kayoko Nishimura, Shin Tsunekawa, and Daisuke Yabe on behalf of G-DIET Investigators
Demand for once-weekly GLP-1 injectable formulations is accelerating across North America, Europe, the GCC, and Asia-Pacific, and India is now the worlds most strategically positioned manufacturing base for cost-efficient, regulation-ready supply
She was started on a slow-release metformin, and at a later stage, semaglutide was re-introduced
Spaniolas said some patients never have used GLP-1s because of the price
Your physician reviews your history, contraindications, and possible side effects before prescribing and monitors you throughout treatment